Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 9/20 | 0.49 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747762 | 0.88 | EGFR (0.60) | EGFRRAF1BRAFSRCKDR | |
| SCHEMBL16747746 | 0.86 | EGFR (0.51) | EGFRRAF1BRAFSRCKDR | |
| SCHEMBL16747712 | 0.86 | EGFR (0.54) | EGFRRAF1BRAFSRCKDR | |
| SCHEMBL18128961 | 0.85 | EGFR (0.46) | EGFRRAF1BRAFSRCKDR | |
| SCHEMBL16747785 | 0.85 | EGFR (0.46) | EGFRRAF1BRAFSRCKDR | |
| SCHEMBL16747734 | 0.85 | SRC (0.56) | EGFRSRCKDR | |
| SCHEMBL16747752 | 0.85 | SRC (0.58) | EGFRSRCKDR | |
| SCHEMBL16747725 | 0.85 | SRC (0.61) | EGFRSRCKDR | |
| SCHEMBL16742194 | 0.84 | EGFR (0.44) | EGFRRAF1BRAFSRCKDR | |
| SCHEMBL16747771 | 0.84 | EGFR (0.61) | EGFRSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105916506-B | Quinazoline derivatives as inhibitors of TAM family kinases | 圣诺康生命科学公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-3071204-B1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2019-02-20 | — | — | EP | disclosed |
| EP-3071204-B1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2019-02-20 | — | — | EP | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077375-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K5, MAP3K1, MAP3K2 | EGFR 1458/4885RAF1 34/4885BRAF 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.